News | June 06, 2022
Merck’s pembrolizumab demonstrates improvement in distant metastasis
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
The product will be launched by NATCO's commercial partner Viatris.
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
The Da Vinci Robotic-Assisted Surgery system, and Advanced Robotic Surgery Centre was inaugurated early this year
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients
The kidney swap transplant procedure provides a solution to a critical shortage of compatible kidneys for patients suffering from kidney failures in India
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
Subscribe To Our Newsletter & Stay Updated
